ReleaseWire

Rituximab (trade names "MabThera" by Roche, "Rituxan" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of B-cell lymphoma. As people understand more about B-cell and its action mechanism, it is acknowledged that besides B-cell malignancies rituximab can also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from 2010 to 2012 respectively.

Description According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.

Description According to WHO, one-third of the world's adults have hypertension. The global market value of antihypertensive drugs is tens of billion dollars.

Autism Spectrum Disorders (ASD) is a chronically underserved market currently dominated by the two approved drugs, both of which are antipsychotics. There is off-label use of a multitude of other drugs which target different core and non-core symptoms of ASD. Since this disorder can first become apparent in very young children there is a need for medications which are safe and effective in the pediatric population. The ASD market is expected to grow remain relatively flat between 2012 and 2018, which is predominantly due to various drug patent expiration, and the introduction of novel therapies in the US and EU countries is not anticipated to offset this expected decline in the market. The new treatments will target some key unmet needs but opportunities will remain for drugs which can effectively target any of the many core and non-core symptoms of ASD, as well as offering an improved safety profile over currently used drugs.

As the air becomes more contaminated, incidence of asthma and chronic obstructive pulmonary diseases also increases. Consequently, more market space is provided for relevant drug manufacturers. Asthma is a common multiple disease mainly caused by inheritance and environment factors. Recurrent attacks of asthma can lead to complications such as chronic obstructive pulmonary disease, emphysema, cor pulmonale, heart failure and respiratory failure. Sometimes it can endanger patients' lives.

Description

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Depression is a common mood disorder that belongs to high-incidence mental diseases worldwide. Its main clinical features are a state of low mood and aversion to activity, and sometimes even suicidal thoughts or behaviors.

GlobalData's clinical trial report, "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Global Market Direct's pharmaceuticals report, "Benitec Biopharma Limited - Product Pipeline Review - 2014" provides data on the Benitec Biopharma Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This is the third review of Alias Kid by a mid 40's music lover; and it explains why, in certain respects at least, this band could be so important for the next 10 years of the UK music industry. If people don't know already then hopefully they will understand by the end of this article. In summary, it is through a band like Alias Kid that we could see 'real' music return to the front of a hopelessly manufactured and increasingly desperate and regurgitating industry.

Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly one-fourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll.

GlobalData's "PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding" report provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry, bearing in mind that these are expected to have significant impact on the future of emerging biotechnology companies in the US and globally. Furthermore, the report identifies regions of the world that are attracting more investments in healthcare and discusses the various factors responsible for this trend. In addition, the report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013.

GlobalData's clinical trial report, "Nevus Global Clinical Trials Review, H1, 2014" provides data on the Nevus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nevus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nevus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global Clinical Trials Review, H1, 2014" provides data on the Choriocarcinoma (Gestational Trophoblastic Neoplasia) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Choriocarcinoma (Gestational Trophoblastic Neoplasia). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Choriocarcinoma (Gestational Trophoblastic Neoplasia). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Brenner Tumor Global Clinical Trials Review, H1, 2014" provides data on the Brenner Tumor clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Brenner Tumor. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Brenner Tumor. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Cutaneous T-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Cutaneous T-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cutaneous T-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cutaneous T-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Description Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.

Accutrition is now selling Kavinace Ultra PM on their website. Kavinace Ultra PM was developed by NeuroScience, a company that specializes in neurotransmitter imbalances.

GlobalData's clinical trial report, "Gastrointestinal Tract Cancer Global Clinical Trials Review, H1, 2014" provides data on the Gastrointestinal Tract Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastrointestinal Tract Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastrointestinal Tract Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Duodenal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Duodenal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Duodenal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Duodenal Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Description According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.

Vitamin B12 is needed by the body for it to be able to carry out certain functions, and deficiency of the vitamin can lead to serious health issues. Among the groups of people who are prone to developing this deficiency are the elderly, and for this, the importance of Vitamin B12 supplementation among them cannot be overstated.